« Return to News | Technology Solutions

StudyManager unveils new trial management software

Thursday, April 28, 2011 12:35 PM

StudyManager, a provider of clinical trial management software and electronic data capture solutions, has released Reveal 3.2. The new features allow research sites, academic medical centers, and hospitals to centralize study information such as trial recruitment, contract negotiation, and compliance efforts.

The 3.2 version includes expanded fields and filters available in Reveal’s reporting tool, allowing clients add more patient, scheduling, and financial information on custom views exportable to Excel; a new, workflow-driven accrual activity “wizard,” allowing clients to track their revenue and receivables, create invoices, trigger holdbacks, and apply payments; increased performance of key screens, including the study “Visits & Procedures” screen, allowing clients to more quickly build their study schedule of events in a grid-style format that matches sponsor documents; and new workflow enhancements, such as a new study search/select field that allows users to more quickly identify and select a study for patient enrollment.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.